MindImmune Therapeutics raises $30M in Series A funding, appoints new CEO
Summary
MindImmune Therapeutics raised $30 million in extended Series A funding. The company also appointed Isaac Stoner as CEO. It focuses on developing treatments for Alzheimer's and other neurodegenerative diseases. Its work targets neuroinflammation as a key driver of disease. The company launched at the University of Rhode Island in 2016.
Funding
Amount
$30.0M
Total raised
Date
November 24, 2025
Announcement date
Investors
-
Lead investors
Company
mindimmune.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected